COVID-19 mRNA-vaccination and all-cause mortality in the adult population in Norway during 2021-2023: a population-based cohort study
Dahl, J.; Tapia, G.; Boas, H.; Landsjoasen Bakken, I. J.; Lovdal Gulseth, H.
Show abstract
IntroductionMost countries worldwide have experienced excess mortality that coincides temporally with the COVID-19 mass vaccination campaigns. This has led to speculation on the potential long-term effects of the vaccines on mortality risk. MethodsThe study was designed as a retrospective cohort study, and included all individuals aged [≥]18 years living in Norway during January 1, 2021, through December 31, 2023. Individuals were categorized as either unvaccinated (received no doses), partially vaccinated (received one or two doses) or fully vaccinated (received three or more doses) from the date of vaccination and onwards. Age-stratified Poisson models were used to estimate incidence rate ratios of death (all causes) between vaccination groups, adjusting for sex, calendar time, county of residence and risk group status (nursing home resident or preexisting condition with increased risk of severe COVID-19). ResultsThe study included 4 645 910 individuals (49.8% women) with 132 963 deaths during follow-up. There was a higher proportion of individuals that were part of a risk group among fully vaccinated individuals compared to unvaccinated individuals in all age groups, and a lower unadjusted rate of death: 51.5 vs 73.6 per 100 000 person years (py) among individuals aged 18-44 years, 295.1 vs 405.3 per 100 000 py among 45-64 years, and 3620.2 vs 4783.8 per 100 000 py among 65 years or older. The adjusted IRR of death for the same age groups were 0.42 (95% CI 0.38-0.47), 0.39 (95% CI 0.37-0.41) and 0.42 (95% CI 0.41-0.43), respectively. The differences in rate of death between vaccination groups were larger among men and peaked during 2022. ConclusionVaccinated individuals had a lower rate of all-cause death during 2021-2023 in Norway. Key messagesIn Norway, as in many Western countries, there has been an excess mortality during 2021-2023, surpassing the numerical count of COVID-19-associated deaths. The excess mortality coincides temporally with the COVID-19 mass vaccination campaigns, but longitudinal data regarding mortality post-vaccination remain sparse. Using real-time national health registry data, we estimate the risk of all-cause mortality by vaccination status in the total adult population in Norway during 2021-2023 and demonstrate a lower rate of all-cause death among vaccinated individuals.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Comparative effectiveness of different primary vaccination courses on mRNA based booster vaccines against SARs-COV-2 infections: A time-varying cohort analysis using trial emulation in the Virus Watch community cohort 94%
- Impacts of COVID-19 on sick leave 91%
- The effect of SARS-CoV-2 testing on healthcare seeking behaviour at primary care level: implications for COVID-19 vaccine effectiveness estimates in test-negative design studies. 90%
Similar papers in this journal
- COVID-19 vaccination and short-term mortality risk: a nationwide self-controlled case series study in The Netherlands 95%
- Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England 91%
- Community-level characteristics of COVID-19 vaccine hesitancy in England: A nationwide cross-sectional study 90%
Similar papers in this journal
- Is the BioNTech-Pfizer COVID-19 vaccination effective in elderly populations? Results from population data from Bavaria, Germany 95%
- Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill – An interim analysis of a nationwide cohort study 95%
- COVID-19 vaccine effectiveness against laboratory confirmed symptomatic SARS-CoV-2 infection, COVID-19 related hospitalizations and deaths, among individuals aged 65 years or more in Portugal: a cohort study based on data-linkage of national registries February-September 2021 95%
Similar papers in this journal
- Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021 97%
- Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July – November 2021 95%
- Ethnic differences in COVID-19 mortality in the second and third waves of the pandemic in England during the vaccine roll-out: a retrospective, population-based cohort study 94%
Similar papers in this journal
- Safety and effectiveness of COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden 96%
- Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study 95%
- Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.